ConcertAI Named One of Fast Company's Most Innovative Companies of 2026

Pioneering Applied AI in Life Sciences & Healthcare

283366 ConcertAI (2) - 2026 Fast Company Most Innovative Companies - Custom Logo-1

Clinical trials are among the most expensive and uncertain stages of drug development. Many promising therapies fail not because the science falls short, but because of avoidable challenges in study design, patient recruitment, and trial execution. ConcertAI helps pharmaceutical companies overcome these barriers by applying AI to large-scale clinical and real-world healthcare data to better predict outcomes, identify bottlenecks, and improve study performance.

Through our Accelerated Clinical Trials (ACT) platform, ConcertAI helps researchers design stronger protocols, select trial sites more strategically, and match the right patients to the right studies. With the addition of the Precision Suite, introduced in 2025, ConcertAI further expanded our generative and agentic AI capabilities to help life sciences organizations analyze data faster and accelerate development. Used by leading biopharma organizations, our solutions help bring greater speed, precision, and confidence to clinical research.

Read the Report